Technical Study: Amgen Inc., Questcor Pharmaceuticals Inc., PDL BioPharma Inc., and BioCryst Pharma Inc. Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, October 17, 2013 LONDON, October 17, 2013 /PRNewswire/ -- The U.S. equity market edged higher on Wednesday, October 16 2013. The S&P 500 ended the day at 1,721.54, up 1.38%; the Dow Jones Industrial Average closed at 15,373.83, up 1.36%; and the NASDAQ Composite finished at 3,839.43, up 1.20%. Shares in the biotechnology industry edged higher, tracking gains in the broader market. The major movers in the industry included Amgen Inc. (NASDAQ: AMGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), PDL BioPharma Inc. (NASDAQ: PDLI), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). AAAResearchReports.com free coverage on AMGN, QCOR, PDLI, and BCRX is available upon registration at: http://www.aaaresearchreports.com/register/ On Wednesday, Amgen Inc.'s stock close at $114.28, up 2.55% from the previous day's closing price of $111.44. The company's shares vacillated between $112.35 and $114.85 during the trading session. A total of 3.49 million shares were traded, which is above the daily average volume of 3.17 million. The company's stock has gained 3.06% in the previous three trading sessions and 9.83% in the last three months, outperforming the S&P 500 which has advanced 1.08% and 2.70% during the respective periods. Further, Amgen Inc.'s stock is trading near its 52-week high of $117.91 and above its 50-day and 200-day moving averages of $110.87 and $101.08, respectively. Download free technical research on AMGN by signing up at: http://www.AAAResearchReports.com/AMGN101713.pdf Shares in Questcor Pharmaceuticals Inc. rallied on Wednesday, extending the gains from the previous trading session. The company's shares ended the day 5.50% higher at $66.73, after trading between $63.30 and $66.95. A total of 1.95 million shares were traded, which is above the daily average volume of 1.80 million. Questcor Pharmaceuticals Inc.'s shares have surged 10.85% in the previous three trading sessions and 37.19% in the last three months, outperforming the S&P 500 which has advanced 1.08% and 2.70% during the respective periods. Moreover, the company's stock is trading above its 50-day and 200-day moving averages of $63.58 and $42.44, respectively. Register now and get access to free analysis on QCOR at: http://www.AAAResearchReports.com/QCOR101713.pdf PDL BioPharma Inc.'s stock ended higher on Wednesday, reversing all the losses from the previous trading session. The company's shares closed the day at $8.03, up 1.39% from the previous day's price of $7.92. The company's shares fluctuated between $7.95 and $8.20 during the trading session. A total of 1.43 million shares were traded, which is below the daily average volume of 1.70 million. The company's stock has gained 1.90% in the last one month and 1.01% in the previous three months, compared to a gain of 1.41% and 2.70% in the S&P 500 during the respective periods. Furthermore, PDL BioPharma Inc.'s stock is trading above its 50-day and 200-day moving averages of $7.98 and $7.66, respectively. Sign up and read our complimentary report on PDLI at: http://www.AAAResearchReports.com/PDLI101713.pdf BioCryst Pharmaceuticals Inc.'s stock advanced on Wednesday, tracking gains in the broader market. The company's shares closed the day 1.22% higher at $6.64, after oscillating between $6.41 and $6.88. A total of 0.94 million shares were traded, which is significantly below the daily average volume of 2.52 million. The company's stock has gained 1.84% in the last one month and 245.83% in the previous three months, outperforming the S&P 500 which has advanced 1.41% and 2.70% during the respective periods. Additionally, BioCryst Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $6.48 and $3.00, respectively. The free report on BCRX can be downloaded by signing up now at: http://www.AAAResearchReports.com/BCRX101713.pdf ---- EDITOR NOTES: 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: email@example.com
Technical Study: Amgen Inc., Questcor Pharmaceuticals Inc., PDL BioPharma Inc., and BioCryst Pharma Inc.
Press spacebar to pause and continue. Press esc to stop.